Seoul, South Korea

Ki Tae Kim

This inventor holds 3 USPTO granted patents and 20 published patent applications and 1 EPO patent. Top assignee: Innobation Bio Co., Ltd.. Active years: 2024-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ki Tae Kim. Retrieved from https://idiyas.com/inventor/ki-tae-kim-yodn0c7n

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.3

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Ki Tae Kim: Innovator in Antibody Research

Introduction

Ki Tae Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies and chimeric antigen receptors.

Latest Patents

Ki Tae Kim holds 3 patents that focus on innovative approaches to treating diseases mediated by B cells. His latest patents include a humanized antibody specific for CD22 and a chimeric antigen receptor utilizing this antibody. These inventions aim to enhance the efficacy of CAR-T cell therapies, which are crucial in combating various B cell-related diseases.

Career Highlights

Ki Tae Kim is currently associated with Innobation Bio Co., Ltd., where he continues to push the boundaries of antibody research. His work has garnered attention for its potential to revolutionize treatment options for patients suffering from B cell-mediated diseases.

Collaborations

He collaborates with notable colleagues, including Seung Koo Kim and Ok Tae Kim, who contribute to the innovative research environment at Innobation Bio Co., Ltd.

Conclusion

Ki Tae Kim's contributions to antibody research and his innovative patents position him as a key figure in the biotechnology industry. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in the treatment of B cell-related diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…